Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

Plain-language summary

This phase 3 randomized controlled trial (SUMMIT) found that tirzepatide significantly reduced the composite risk of death from cardiovascular causes or worsening heart failure compared to placebo in patients with obesity and heart failure with preserved ejection fraction. Participants also showed meaningful improvements in health status and functional outcomes. The study reinforces the broad cardiometabolic benefits of this dual GIP/GLP-1 receptor agonist beyond glycemic and weight control.